Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia by Nilsson, Malin S. et al.
Complete remission after the first cycle of induction
chemotherapy determines the clinical efficacy of
relapse-preventive immunotherapy in acute myeloid leukaemia
Downloaded from: https://research.chalmers.se, 2021-08-31 13:00 UTC
Citation for the original published paper (version of record):
Nilsson, M., Hallner, A., Brune, M. et al (2020)
Complete remission after the first cycle of induction chemotherapy determines the clinical
efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia
British Journal of Haematology, 188(4): e49-e53
http://dx.doi.org/10.1111/bjh.16320
N.B. When citing this work, cite the original published paper.
research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology.
It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004.
research.chalmers.se is administrated and maintained by Chalmers Library
(article starts on next page)
Supporting Information
Additional supporting information may be found online in
the Supporting Information section at the end of the article.
Table S1. Expected ATL cases in Brazil and its regions
estimated accounting for differences in HTLV-1 prevalence
between Brazil‘s regions, age and gender.
References
da Barbosa, S.F.C. (2012) Soropreval̂encia da
infecc~ao pelo vırus linfotropico de celulas T huma-
nas em portadores de doencas linfoproliferativas




Carneiro-Proietti, A.B.F., Ribas, J.G.R., Catalan-
Soares, B.C., Martins, M.L., Brito-Melo, G.E.A.,
Martins-Filho, O.A., Pinheiro, S.R., de Araujo,
A.Q.-C., Galv~ao-Castro, B., de Oliveira, M.S.P.,
Guedes, A.C. & Proietti, F.A. (2002) Infecc~ao e
doenca pelos vırus linfotropicos humanos de
celulas T (HTLV-I/II) no Brasil. Revista da Soci-
edade Brasileira de Medicina Tropical, 35, 499–
508. Available at: http://www.scielo.br/scielo.
php?script=sci_arttext&pxml:id=S0037-
86822002000500013&lng=pt&tlng=pt.
Gessain, A. & Cassar, O. (2012) Epidemiological
aspects and world distribution of HTLV-1 Infec-




Iwanaga, M., Watanabe, T. & Yamaguchi, K.
(2012) Adult T-cell leukemia: a review of epi-
demiological evidence. Frontiers in microbiology,
3, 322. Available at: http://www.ncbi.nlm.nih.
gov/pubmed/22973265.
Ministerio da Saude do Brasil (2012) Informac~ao
dos Registros Hospitalares de Câncer como
estrategia de transformac~ao Perfil do Instituto
Nacional de Câncer Jose Alencar Gomes da Silva
em 25 anos. Available at: http://bvsms.saude.
gov.br/bvs/publicacoes/inca/Informacao_dos_reg
istros_hospitalares.pdf.
Nunes, D., Boa-Sorte, N., Grassi, M.F.R., Taylor,
G.P., Teixeira, M.G., Barreto, M.L., Dourado, I.
& Galv~ao-Castro, B. (2017) HTLV-1 is predomi-
nantly sexually transmitted in Salvador, the city
with the highest HTLV-1 prevalence in Brazil.
PLoS ONE, 12, e0171303. Available at: http://
www.ncbi.nlm.nih.gov/pubmed/28158226.
Oliveira, P.D., de Carvalho, R.F. & Bittencourt,
A.L. (2017) Adult T-cell leukemia/lymphoma in
south and central America and the Caribbean:
systematic search and review. International Jour-
nal of STD & AIDS, 28, 217–228. Available at:
http://journals.sagepub.com/doi/10.1177/
0956462416684461.
Oliveira, P.D., Kachimarek, A.C. & Bittencourt,
A.L. (2018) Early onset of HTLV-1 associated
myelopathy/tropical spastic paraparesis (HAM/
TSP) and adult T-cell leukemia/lymphoma
(ATL): systematic search and review. Journal of
Tropical Pediatrics, 64, 151–161. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/28582585.
Pombo De Oliveira, M.S., Loureiro, P., Bitten-
court, A., Chiattone, C., Borducchi, D., De Car-
valho, S.M., Barbosa, H.S., Rios, M., Sill, A.,
Cleghorn, F. & Blattner, W. (1999) Geographic
diversity of adult t-cell leukemia/lymphoma
in Brazil. The Brazilian ATLL Study Group.
International journal of cancer, 83, 291–8. Avail-
able at: http://www.ncbi.nlm.nih.gov/pubmed/
10495418.
Rosadas, C., Malik, B., Taylor, G.P. & Puccioni-
Sohler, M. (2018) Estimation of HTLV-1 vertical
transmission cases in Brazil per annum. PLOS
Neglected Tropical Diseases, 12, e0006913.
Zihlmann, K.F., de Alvarenga, A.T. & Casseb, J.
(2012) Living Invisible: HTLV-1-infected per-
sons and the lack of care in public health. PLoS
Neglected Tropical Diseases, 6, e1705. Available
at: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC3373594/pdf/pntd.0001705.pdf.
Complete remission after the first cycle of induction
chemotherapy determines the clinical efficacy of relapse-
preventive immunotherapy in acute myeloid leukaemia
Relapse after the completion of induction and consolidation
chemotherapy remains a significant cause of mortality in the
post-chemotherapy phase of acute myeloid leukaemia (AML).
Several studies have questioned whether AML patients who
require two or more courses of induction chemotherapy to
attain complete remission (CR) are at increased risk of relapse
or death. While studies performed in the 1980’s and 1990’s
yielded inconclusive results (Rowe et al., 2010), contemporary
studies have identified that needing more than one cycle of
induction chemotherapy to achieve CR is a risk factor for
relapse and death in younger adult patients (Othus et al.,
2019).
Aspects of immunity are relevant to the relapse risk in
AML and several immunotherapies aimed at preventing
relapse have been developed (Martner et al., 2013; Weinstock
et al., 2017; Beyar-Katz & Gill, 2018; Liu et al., 2019).
Immunotherapy with histamine dihydrochloride in conjunc-
tion with low-dose interleukin-2 (HDC/IL-2) is approved for
relapse prevention in AML patients within the European
Union (EU). For this study, we analysed the potential impact
of previous induction chemotherapy on the clinical efficacy
of HDC/IL-2.
Three hundred and twenty patients with AML (18–
84 years, median 55), who were not eligible for allogeneic
stem cell transplantation, were randomly assigned to receive
relapse-preventive immunotherapy with HDC/IL-2 or no
treatment (control group) in a phase III trial. HDC/IL-2 was
initiated in CR after consolidation chemotherapy (Brune
et al., 2006). Patients in the treatment arm were scheduled to
receive 10 consecutive three-week cycles of HDC/IL2 with
three- (cycles 1–3) or six-week (cycles 4–10) rest periods. In
each cycle, these patients received HDC (Noventia Pharma,
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Fig 1. Panels A and B show Kaplan-Meier plots of LFS and OS in HDC/IL-2 treated patients or control patients who attained CR1 after the first
cycle of induction chemotherapy. Panels C and D show corresponding results in patients <60 years old. Panels E and F show LFS and OS in
patients (all ages) who required >1 induction cycle to attain CR1. Statistical analysis was performed by the logrank test.
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Milan, Italy) at 05 mg and human recombinant low-dose
IL-2 (aldesleukin; 16 400 IU/kg; Chiron Corporation, Emery-
ville, CA) subcutaneously twice a day. After 18 months of
treatment, patients were monitored for at least 18 additional
months. The median follow-up time was 48 months.
In the CR1 population (n = 261), the number of induc-
tion cycles was known in 260 patients, and 203 (78%) of
these attained CR after one induction cycle. Among the 57
remaining patients, 47 attained CR after two cycles, while
three (n = 7) or four (n = 3) cycles were required to induce
CR in 10 patients. Among control patients, there was a non-
significant trend towards inferior clinical outcome in terms
of leukemia-free survival (LFS, defined as the time from
inclusion to relapse or death) in those who required more
than one induction to attain CR, with a similar trend in
younger patients (<60 years old; Figure S1A-B). In the HDC/
IL-2 arm, outcome was significantly superior in patients who
attained CR1 after one induction for all patients as well as
for younger patients (Figure S1C-D). In multivariable analy-
ses, it was found that the number of induction cycles
required to attain CR independently predicted outcome for
patients in the treatment arm (Table S1).
We compared clinical outcomes for HDC/IL-2-treated and
control patients who achieved CR after one cycle of induction.
In this group, the HDC/IL-2 arm was significantly superior to
the control arm for LFS, with a similar trend for overall sur-
vival (OS; Figure 1A-B). In patients less than 60 years old,
treatment with HDC/IL-2 entailed significantly improved LFS
and OS (Figure 1C-D). The survival advantage for patients in
the treatment arm over the control arm remained significant
in multivariable analyses (Table I), correcting for predefined
potential confounders (Brune et al., 2006). Treatment with
HDC/IL-2 did not affect LFS or OS in patients who required
more than one cycle of induction to attain CR1 (Figure 1E-F)
and was not significantly beneficial in older patients
(>60 years old; data not shown). A test of interaction on the
effect of HDC/IL-2 versus controls for LFS supported the find-
ing that it was more pronounced in younger patients who
attained CR after one (HR = 048) versus more than one
(HR = 133) cycle of induction (P = 004).
The HDC component of the HDC/IL-2 regimen aims at
countering immunosuppression triggered by reactive oxygen
species, formed by the NOX2 enzyme expressed by normal
and malignant myeloid cells (Martner et al., 2013; Martner
et al., 2019). In AML, functional NOX2 is co-expressed with
histamine H2 receptors (H2R) by leukaemic cells of the M4
and M5 FAB classes (Aurelius et al., 2012a; Aurelius et al.,
2012b). We analysed the impact of induction chemotherapy
on treatment efficacy in younger patients with FAB M4/M5
AML and observed pronounced efficacy of HDC/IL-2 versus
controls in terms of LFS and OS in patients who attained
CR1 after one induction in univariable and multivariable
analysis (Figure S2, Table I).
We conclude that the clinical efficacy of relapse-preventive
immunotherapy with HDC/IL-2 hinges on the effectiveness
of induction chemotherapy. In this regard, our results con-
firm and extend previous findings in a single-arm phase IV
trial in which 84 AML patients in CR1 received HDC/IL-2
(Aurelius et al., 2019). In addition, similar results of favour-
able outcome in patients achieving CR after one versus sev-
eral cycles of induction were obtained in AML patients
undergoing allogeneic transplantation (Walter et al., 2013).
Collectively, these results suggest that efficient elimination of
leukemic cells during induction treatment favours immune-
mediated clearance of residual leukaemia, thus preventing
relapse and death in the post-chemotherapy phase.
Within the group of patients attaining CR after one
induction cycle, our data also point to subgroups of patients,
including FAB-M4/M5 AML, in whom the clinical efficacy of
HDC/IL-2 for relapse prevention is pronounced. These
results thus provide means to identify patients who are likely
to benefit from immunotherapy and, conversely, patients in
Table I. Cox regression analysis of effects of HDC/IL-2 treatment versus control on LFS or OS in patients in CR1 who attained CR after one
induction cycle. Covariates that tended to affect LFS or OS in univariable analyses (P-values below 01) were included in multivariable analyses.
Patient groups Outcome
Univariable analysis Multivariable analysis†
HR† 95% CI‡ P-value HR 95% CI P-value
All patients LFS 065 046–092 001 064 045–091 001
OS 071 048–105 009 076 051–114 018
<60 years LFS 048 030–076 0002 046 029–072 00008
OS 053 031–092 002 049 028–085 001
<60 years M4/M5§ LFS 028 013–062 0002 028 013–062 0002
OS 028 010–074 001 033 012–091 003
*Covariates considered: age; gender (female vs. male); karyotype (favourable vs. intermediate vs. unfavourable); French-American-British (FAB)
class M0/M1/M5/M6 (yes vs. no); FAB class M2/M3/M4 (yes vs. no); >3 days cytarabine treatment (yes vs. no); secondary AML (yes vs. no); and
months from CR1 to random assignment (>6 mo vs. ≤6 mo).
†HR = hazard ratio between HDC/IL-2 and control.
‡CI = confidence interval.
§M4/M5 = French-American-British class M4 and M5.
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whom the therapy is inefficacious. The exploratory nature of
these results should be emphasised.
In summary, our results imply that the efficiency of
induction chemotherapy independently determines the clini-
cal benefit of relapse-preventive immunotherapy with HDC/
IL-2 in adult AML patients who are not candidates for allo-
geneic transplantation. This finding, along with similar
results achieved in patients receiving allo-SCT, suggests that
future immunotherapy trials should take the efficiency of
induction therapy into account.
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Table S1. Cox regression analysis of the effect of 1 versus
>1 induction cycle of chemotherapy on LFS or OS in
patients in CR1. Covariates with P-values below 0.1 in
univariable analyses were included in multivariable
analyses.
Figure S1. Kaplan-Meier plots of LFS in all control arm
patients in CR1 (A) and in younger control patients (<60
years old, B) who attained CR after 1 versus >1 course of
induction chemotherapy. Panels C and D show correspond-
ing results in the HDC/IL-2 arm. Statistics by the logrank
test.
Figure S2. Kaplan-Meier plots of LFS (A) and OS (B) in
younger patients (<60 years old) with AML of FAB M4/M5
classes receiving HDC/IL-2 or control who attained CR1 after
the first course of induction chemotherapy. Statistics by the
logrank test.
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In trans early mosaic mutational escape and novel phenotypic
features of germline SAMD9 mutation
Mutations in SAMD9 or SAMD9L are found in patients with
familial predisposition to myelodysplastic syndrome (MDS)
and acute myeloid leukaemia (AML) associated with both
MIRAGE syndrome (Myelodysplasia, Infection, Restriction of
growth, Adrenal hypoplasia, Genital phenotypes, and
Enteropathy) and ATXPC (ataxia-pancytopenia syndrome) (Li
et al., 1981; Narumi et al., 2016; Chen et al., 2016), respec-
tively. The wild-type (WT) function of SAMD9 and SAMD9L
in haematopoietic cell lines is antiproliferative. Germline
mutations are thought to be gain-of-function (GOF) muta-
tions, exacerbating the antiproliferative effects of the WT gene
(Tesi et al., 2017; Buonocore et al., 2017; Davidsson et al.,
2018). Functional somatic reversion through either loss of
heterozygosity (7 or 7q-) or uniparental disomy (UPD), or
through acquisition of loss of function (LOF) mutations, has
been described in affected individuals. Thus far, LOF muta-
tions have been described in cis for SAMD9, but rarely in trans
for SAMD9L (Nagata et al., 2018; Wong et al., 2018). Here we
present a four-generation pedigree affected by AML and MDS,
with novel disease features and a reversion mutation in trans,
consistent with germline mosaicism.
The proband (III-1) presented in 1986 aged 10 with a
history of excessive bruising. She was one of four siblings,
two of which were stillborn. She was also noted to have
an extensive family history of MDS and AML; specifically,
her mother (II-1) had MDS, an aunt (II-4) died of AML
aged 11 following MDS, a cousin (III-5) died of AML
aged eight and her mother’s cousin (II-8) died of leukae-
mia (Fig 1A). Her haematological parameters at presenta-
tion were normal, except for abnormal platelet function
tests. In 1998 (aged 22) she developed tri-lineage cytope-
nias. Bone marrow aspirate (BMA) at this time showed
MDS with 7q- in 5/30 metaphases (46,XX,del(7)(q22q33)
[5]/46,XX[25]). Additional multisystem abnormalities were
identified over her 20-year follow-up; imaging undertaken
for urinary tract infections, adenomyosis and an iliofemoral
DVT in 2002 (aged 26) revealed duplex left kidney and
ureters, intermediate situs, including right-sided stomach
and spleen, multiple small splenenculi, reversed pancreas,
midline liver, mispositioned transverse colon and abnormal
anatomy of venous drainage.
Follow-up BMA in 2004 (aged 28) showed MDS with nor-
mal karyotype (NK) with similar findings in 2015 (aged 39).
Illumina Trusight myeloid panel showed an MDS-associated
ZRSR2 variant (pGly438_Ser439insSerArg).
Her daughter, IV-1, was born in 1996 at 28 weeks due
to severe IUGR. Blood count at birth showed thrombocy-
topenia (90x109/l), presumed to be due to prematurity.
However, aged two, she was noted to have anaemia (Hb
9.1g/dl) as well as thrombocytopenia (65x109/l). A BMA
showed MDS with NK. She underwent an unrelated donor
transplant at the age of four. Pre-transplant assessment
noted that she had global developmental delay. She died
two months post-transplant due to Epstein-Barr virus-
related disease.
The proband had five additional pregnancies. IV-3 was
complicated by severe polyhydramnios and the pregnancy
was terminated because of concerns regarding congenital
anomalies. IV-5 is alive and well, aged 10.
Informed consent was obtained from the UCL/UCLH Bio-
bank for Studying Health and Disease. Whole exome
sequencing was undertaken on stored bone marrow DNA of
the proband from 2015, which identified two non-synony-
mous base changes in SAMD9 c.2958C> G – resulting in
S986C – and c.1447C> G – resulting in p.L483V (Fig 1B). In
silico analyses of these variants suggested both mutations
were likely to be pathogenic (Fig 1C).
To determine if the mutations found in the proband
were present in other family members, we undertook tar-
geted deep sequencing of the regions surrounding the
SAMD9 variants in IV-1 and the proband’s mother (II-1)
along with additional available samples from IV-5 and III-
1 (Fig 1D). III-1, IV-1 and II-1 carried L483V at allele fre-
quencies consistent with germline origin. The S986C vari-
ant was present only in samples from III-1. Here it was
present at an allele frequency of 21% in the peripheral
blood (2001) and 304% in the BMA from 2015. Matched
buccal swab (2015) also showed this variant but at a lower
allele frequency (17%). To determine whether this was due
to blood contamination, we obtained nail clippings from
III-1. This revealed the presence of the S986C mutation at
a low frequency of 36%. This suggests that the proband
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